The United States and the United Kingdom announced a high-level trade deal Monday that would exempt U.K. pharmaceuticals from ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...

Explore the shift towards localization and innovation in the Middle East's pharmaceutical industry, with insights from experts about market growth, regulatory challenges, and the role of technology in ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

According to DataM Intelligence, the Orphan Drugs Market Size was USD 223.76 billion in 2023 and is forecasted to soar to USD 486.51 billion by 2032, expanding at a strong CAGR of 9.1% between 2024 ...